
Keystone worked on behalf of Amgen in their acquisition of Horizon Therapeutics, a smaller biotech firm with two differentiated drugs. A Keystone expert conducted analyses on the market access conditions that would prevent Amgen from leveraging Horizon's drugs in an anticompetitive manner. The merger was conditionally cleared by the FTC.